Notably, global inhibition of NALCN may cause abnormal functional outcomes, such as respiratory depression; therefore, the discovery of inhibitors targeting the peripheral nervous system, such as the DRG, may be more effective and safer. This evidence concerns the gene NALCN and Respiratory insufficiency due to muscle weakness.